October 31, 2006 -- Biomira bought ProlX Pharmaceuticals, with three cancer drugs in development, for $25.5 million; Avanir received an Approvable letter for Zenvia, which sent the stock lower; CytRx won Orphan Drug designation for its ALS drug candidate in Europe; Adolor returned the rights for the LidoPAIN analgesic patch to EpiCept; Regeneron said Interleukin-1 Trap was effective against a rare genetic disease called CAPS; the US CDC will evaluate a bird flu vaccine from Novovax; Schering began a trial giving lymphoma patients a combination of Leukine and Rituxan; Array will take its anti-inflammatory drug into the clinic; and Introgen will ask for European approval of Advexin p53 therapy for Li-Fraumeni Syndrome. The Centient Biotech 200™ gained 13 points to end at 4001, a rise of .33%. More details...
